Dan M, Poch F, Leibson L, Smetana S, Priel I
Infectious Diseases Unit, E. Wolfson Hospital, Holon, Israel.
J Hosp Infect. 1999 Nov;43(3):231-8. doi: 10.1053/jhin.1998.0641.
The prevalence of rectal carriage of vancomycin-resistant enterococci (VRE) in two high-risk populations--61 patients admitted to ICU and 92 patients on renal dialysis--was studied longitudinally over a period of six months in a 650-bed general hospital. ICU patients were swabbed weekly and dialysis patients monthly. Enterococcal isolates were fully identified using the ATB identification system, and MICs were determined according to the NCCLS recommendations. Enterococci were isolated in 52 (83.6%) ICU patients and 86 (93.4%) dialysis patients. VRE were recovered at least once in 14 (27%) ICU patients and four (4.8%) dialysis patients. All VRE isolates (MIC of vancomycin > or = 256 micrograms/mL) were resistant to teicoplanin (MIC > or = 32 micrograms/mL; vanA phenotype), 87.5% were ampicillin-resistant, and 92% showed high-level resistance to gentamicin; 88% were E. faecium. The main risk factors for acquisition of VRE included duration of hospitalization in the six months preceding entry into the study and during the survey (P = 0.009 and 0.007 respectively, for ICU patients), and duration of antibiotic administration (P = 0.005, for ICU patients). The impact of vancomycin was most prominent (P = 0.005 for receipt and 0.06 for duration of administration, in ICU patients). Six of the 18 VRE carriers developed bacteraemia, six isolates being vancomycin-susceptible and one vancomycin-resistant (one patient had both). In this study, the first in Israel, a low rectal carriage rate occurred in renal dialysis patients and antibiotic use was the most important risk factor for VRE colonization.
在一家拥有650张床位的综合医院中,对两个高危人群——61名入住重症监护病房(ICU)的患者和92名接受肾透析的患者——进行了为期六个月的纵向研究,以了解耐万古霉素肠球菌(VRE)在直肠中的携带情况。ICU患者每周进行拭子采样,透析患者每月进行采样。使用ATB鉴定系统对肠球菌分离株进行全面鉴定,并根据美国国家临床实验室标准委员会(NCCLS)的建议测定最低抑菌浓度(MIC)。在52名(83.6%)ICU患者和86名(93.4%)透析患者中分离出肠球菌。14名(27%)ICU患者和4名(4.8%)透析患者至少有一次检测到VRE。所有VRE分离株(万古霉素MIC≥256微克/毫升)对替考拉宁耐药(MIC≥32微克/毫升;vanA表型),87.5%对氨苄西林耐药,92%对庆大霉素表现出高水平耐药;88%为粪肠球菌。获得VRE的主要危险因素包括进入研究前六个月以及调查期间的住院时间(ICU患者分别为P = 0.009和0.007),以及抗生素使用时间(ICU患者为P = 0.005)。万古霉素的影响最为显著(ICU患者中接受使用的P = 0.005,使用时间的P = 0.06)。18名VRE携带者中有6人发生菌血症,6株分离株对万古霉素敏感,1株对万古霉素耐药(1名患者同时有这两种情况)。在以色列的这项首次研究中,肾透析患者的直肠携带率较低,抗生素使用是VRE定植的最重要危险因素。